For laboratory research use only — not for human consumption
For laboratory research use only — not for human consumption
Comparison
A neutral, structural comparison of GHK-Cu and Retatrutide as research compounds — written for researchers evaluating the two. It describes structure and research context only; it makes no human-use, dosing, or therapeutic claim. Both are supplied for in-vitro laboratory research use only.
| GHK-Cu | Retatrutide | |
|---|---|---|
| Class | Copper-binding tripeptide complex | Triple-agonist peptide (GLP-1 / GIP / glucagon) |
| Research area | Copper-peptide & matrix-signalling research | Metabolic & receptor-signalling research |
| CAS number | 49557-75-7 | 2381089-83-2 |
| Molecular formula | C14H22CuN6O4 | C221H342N46O68 |
| Sequence | Gly-His-Lys · Cu(II) | — |
| HPLC purity | 99.72% | 99.66% |
GHK-Cu is a naturally occurring copper-binding tripeptide complex (glycyl-L-histidyl-L-lysine bound to copper(II)) studied in laboratory research into matrix remodelling and copper-transport signalling. Its well-defined structure makes it a common reference compound in copper-peptide research.
Retatrutide is a synthetic triple-agonist peptide investigated in laboratory research into metabolic and receptor-signalling pathways. It is studied for its simultaneous activity across the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor systems — the reason it appears frequently in comparative metabolic-research literature alongside single-agonist (GLP-1) and dual-agonist (GLP-1/GIP) reference peptides.
Both compounds are supplied strictly for in-vitro laboratory research use only. Not for human or veterinary use. This comparison is structural and contextual and does not constitute advice on use.
